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Background/aim: Tests specific for VCA IgM, VCA IgG, and EBNA IgG are used to diagnose Epstein–Barr virus (EBV) infections and
interpret disease status. The immunofluorescence assay (IFA) is accepted as the “gold standard” test. The purpose of this study was to
evaluate the performance of 4 methods in comparison with IFA.
Materials and methods: In total, 101 serum samples were obtained from clinically suspected cases of EBV infection between May
2010 and May 2012 and evaluated by IFA. All serum samples were analyzed by an immunoblot assay, enzyme-linked fluorescent assay
(ELFA), enzyme immunoassay (EIA), and immunochromatographic assay (ICA).
Results: ELFA and ICA results were in good agreement with IFA for the detection of VCA IgM, VCA IgG, and EBNA IgG. The results
of the immunoblot assay agreed less well with IFA for EBNA IgG, while EIA results were not in agreement with IFA for EBNA IgG or
VCA IgM.
Conclusion: Among the tests studied, ELFA and ICA appear to be suitable methods for the diagnosis and staging of EBV when
considering cost-effectiveness, turnaround times, need for a specialist, and IFA concordance.
Key words: Epstein–Barr virus, ELISA, immunoblot assay, immunochromatographic assay

1. Introduction
The Epstein–Barr virus (EBV) is a member of the
Gammaherpesvirinae, a subfamily of the family
Herpesviridae. It is one of the most common human
viruses and is distributed worldwide. More than 90% of
the population becomes infected with EBV at some time
during their life. The virus is acquired during childhood
and usually does not cause any symptoms. However,
approximately 10%–20% of adolescents and young adults in
Western societies develop acute infectious mononucleosis.
EBV is also associated with certain cancers, specifically
Burkitt’s lymphoma, nasopharyngeal carcinoma, Hodgkin’s
disease, and immunoblastic lymphoma (1,2).
Nonspecific and EBV-specific laboratory tests are used
to diagnose EBV infection. The detection of heterophile
antibodies, referred to as the Paul–Bunnell test, is a
nonspecific test commonly used around the world for the
diagnosis of EBV infection. However, this test produces false
negative results in approximately 40% of children tested.
Even higher percentages (92.9%) of false positive results
are observed in young adults, although the sensitivity is
higher in adults (2–4). In addition, heterophile antibodies
* Correspondence: kocogluesra@yahoo.com
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are nonspecific and may also be present in non-EBV
infections, malignancies, and autoimmune diseases (2,5).
Negative results for the detection of heterophile antibodies
are not evidence of the absence of EBV infection in
children. Likewise, positive results do not always confirm
the presence of acute EBV infection in these patients.
The detection of 3 analytes (VCA IgM, VCA IgG,
and EBNA IgG) in combination is a specific test used for
the interpretation of primary and past infection, and for
the determination of the absence of EBV infection (6).
A primary infection is characterized by the detection of
VCA IgM and VCA IgG, with negativity for EBNA-1 IgG.
Past infections are characterized by EBNA-1 IgG and VCA
IgG detection, with negativity for VCA IgM. Evaluation of
EA-D IgG may also be useful for determining the disease
state when various serological patterns are encountered.
Detection of EBNA-1 IgG excludes acute EBV infection,
which is important during evaluation (2).
Several methods can be used for the serological
diagnosis of EBV infection. Of these, the
immunofluorescence assay (IFA) is accepted as the “gold
standard” (7). However, standardization of this method is
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difficult due to its requirement for experienced personnel,
the sometimes subjective interpretations, and timeconsuming procedure. In this study, we evaluated the
performance of 4 methods [immunoblot assay, enzymelinked fluorescent assay (ELFA), enzyme immunoassay
(EIA), and immunochromatographic assay (ICA)] in
comparison with IFA.
2. Materials and methods
This study was approved by the local ethics committee.
2.1. Serum samples
In total, 101 serum samples obtained from clinically
suspected cases of EBV infection between May 2010 and
May 2012 were evaluated by IFA. The serum samples were
stored at –20 °C following a diagnosis of EBV infection by
IFA. Analysis of the samples using the 4 test methods was
performed at room temperature without refreezing.
2.2. IFA
EBV-specific anti-VCA IgM, anti-VCA IgG, anti-EBNA
IgG, and anti-EA IgG antibodies were assayed by the IFA
test (Euroimmun, Germany) as a reference method. Patient
samples were diluted 1:10 in PBS-Tween, and negative and
positive controls were included in all tests. Control serum
was added directly to the corresponding reaction field of
the reagent tray. The tests were independently evaluated by
3 experienced specialists educated in this field.
2.3. Immunoblot assay
IgG and IgM antibodies against EBV VCA (gp125 and
p19), EBV nuclear antigens (EBNA-1 and p22), and EA-D
were analyzed using the Euroline anti-EBV profile 2
immunoblotting assay (Euroline, Euroimmun, Germany).
Patient samples were diluted 1:51 and mixed well by
vortexing.
2.4. ELFA
EBV VCA IgM, EBV VCA/EA IgG, and EBV EBNA IgG
were detected using this assay, which contains p18 for
VCA, p54 for EA, and p72 for EBNA (VIDAS, BioMérieux,
France). The results are calculated automatically and
expressed as an index of the ratio between the tested
sample and a positive standard.
2.5. EIA
EBV-specific anti-VCA IgM, anti-VCA IgG, anti-EBNA
IgG, and anti-EA IgG antibodies were detected using
micro enzyme-linked immunosorbent assay (microELISA;
Euroimmun, Germany). The samples were assayed at a
1:101 dilution. A calibration, negative control, and positive
control were included in all tests.
2.6. ICA
EBV-specific anti-VCA IgM, anti-VCA IgG, and
anti-EBNA IgG were investigated according to the
manufacturer’s instructions (VIRapid, Vircell, Spain). The

results of the immunoblot assay, ELFA, EIA, and ICA were
compared with that of the reference method (IFA).
2.7. Classification of disease state
The specimens were categorized as seronegative, primary
infection, reactivation, or past infection based on the EBVspecific antibody profiles described by Klutts (8).
2.8. Statistical analysis
Statistical analyses were performed using SPSS 15
(SPSS Inc., USA). Kappa statistics were used to assess
the agreement between tests, and the kappa values
were evaluated according to Landis and Koch. Levels of
agreement for the kappa value results were categorized
as “almost perfect” (0.81 to 1.0), “substantial agreement”
(0.61 to 0.80), “mostly in agreement” (0.41 to 0.60), and
“poor to fair” (0 to 0.40) (9).
3. Results
Eleven primary infections, 1 past infection characterized
by loss of EBNA, 60 past infections, 6 reactivations, 21
seronegative results, and 2 unknown results were obtained
by IFA. Of the 11 serum samples diagnosed as primary
infection by IFA, 10 were evaluated as primary infections
by immunoblot assay, 6 by ELFA and ICA, and 3 by EIA.
Fifty of the 60 serum samples diagnosed as past infections
by IFA were evaluated as past infections by the immunoblot
assay, 54 by ELFA, 47 by EIA, and 48 by ICA. Reactivations
were not obtained by tests other than IFA (Table 1).
The agreement rate for anti-VCA IgM detection with
respect to the reference test was 0.824 for immunoblot
assay, 0.622 for ELFA, 0.076 for EIA, and 0.509 for ICA.
These results indicate almost-perfect agreement between
immunoblot assay and IFA for anti-VCA IgM detection,
while the agreement classification for EIA was interpreted
as “poor to fair”. The agreement of ELFA and ICA with
IFA was interpreted as “substantial agreement” and
“mostly in agreement”, respectively. The sensitivity was
between 33.3% (EIA) and 91.7% (immunoblot assays),
while the specificity was between 77.5% (EIA) and 96.6%
(immunoblot assays) (Table 2).
An agreement rate of 0.653 was obtained for the
immunoblot assay, 0.712 for ELFA, 0.734 for EIA, and
0.599 for ICA for anti-VCA IgG when compared with
the reference test. While there was substantial agreement
between the immunoblot assay, ELFA, EIA, and IFA for
anti-VCA IgG, the agreement between ICA and IFA was
interpreted as “mostly in agreement”. The sensitivity was
between 84.6% (ICA) and 97.4% (immunoblot assays),
while the specificity was between 60.9% (immunoblot
assays) and 87% (ELFA) (Table 3).
An agreement rate of 0.300 was obtained for the
immunoblot assay, 0.568 for ELFA, 0.297 for EIA, and
0.590 for ICA for anti-EBNA IgG when compared with
the reference test. While the results indicated that ELFA
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Table 1. Comparison of assay interpretation.
IFA

ICA

EIA

ELFA

Immunoblot-based
assay

Assay interpretation
Primary infection

Primary
infection

EBNA lost,
past infection

Past
infection

Reactivation

Unknown

Seronegative

Primary infection

10

0

1

0

0

0

EBNA lost, past infection

0

0

7

0

1

0

Past infection

1

1

50

6

1

1

Reactivation

0

0

0

0

0

0

Unknown

0

0

0

0

0

6

Seronegative

0

0

2

0

0

14

Primary infection

6

1

0

0

0

0

EBNA lost, past infection

0

0

0

0

0

0

Past infection

4

0

54

4

2

1

Reactivation

1

0

0

0

0

0

Unknown

0

0

4

1

0

2

Seronegative

0

0

2

1

0

18

Primary infection

3

0

11

2

0

0

EBNA lost, past infection

0

0

0

0

0

0

Past infection

8

1

47

4

2

1

Reactivation

0

0

0

0

0

0

Unknown

0

0

0

0

0

3

Seronegative

0

0

2

0

0

17

Primary infection

6

1

1

1

0

1

EBNA lost, past infection

0

0

0

0

0

0

Past infection

3

0

48

3

2

1

Reactivation

0

0

0

0

0

0

Unknown

2

0

11

2

0

1

Seronegative

0

0

0

0

0

18

Table 2. Agreement of assays for VCA IgM.
IFA

Assay interpretation
Positive
Immunoblot-based
assay
ELFA
EIA
ICA

916

Negative
Positive

11

3

Negative

1

86

Positive

8

4

Negative

4

85

Positive

4

20

Negative

8

69

Positive

9

10

Negative

3

79

Sensitivity (%)

Specificity (%)

Kappa

91.7

96.6

0.824

66.7

95.5

0.622

33.3

77.5

0.076

75

88.8

0.509
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Table 3. Agreement of assays for VCA IgG.
IFA

Assay interpretation
Positive
Immunoblot-based
assay
ELFA

EIA

ICA

Negative
Positive

76

9

Negative

2

14

Positive

70

3

Negative

8

20

Positive

75

6

Negative

3

17

Positive

66

4

Negative

12

19

and ICA mostly agreed with IFA for anti-EBNA IgG,
the agreement of the immunoblot assay and EIA was
interpreted as “poor to fair”. The sensitivity was between
74.6% (EIA) and 89.8% (immunoblot assays), while the
specificity was between 38.1% (immunoblot assays) and
73.8% (ICA) (Table 4).
The ELFA test required 40 min to determine the EBV
status, while 190 min was required for IFA, 130 min for
both the immunoblot assay and EIA, and 20 min for ICA.
The immunoblot assay and ELFA were more expensive than
the others. EIA and IFA required subjective comments by
experienced personnel. Specialist equipment was needed
for all tests investigated, with the exception of ICA.

Sensitivity (%)

Specificity (%)

Kappa

97.4

60.9

0.653

89.7

87

0.712

96.2

74

0.734

84.6

82.7

0.599

4. Discussion
To determine the stage of EBV infection (acute, past, or
reactivation), several parameters must be evaluated. When
diagnostic tests for EBV infection are evaluated, the results
are usually compared to the “gold standard” test, IFA. In
this study, we evaluated the diagnostic performance of
2 immunoassays, an immunoblot assay, and an ICA by
comparing them with IFA. We identified good correlations
between the 4 methods and IFA for the detection of antiVCA IgG. Detection of anti-VCA IgM by the immunoblot
assay, ELFA, and ICA showed good correlation with IFA
results. ELFA and ICA correlated well with IFA for antiEBNA IgG detection. The agreement of ELFA, EIA, and
ICA with IFA was interpreted as “poor to fair”.

Table 4. Agreement of assays for EBNA IgG.
IFA

Assay interpretation
Positive
Immunoblot-based
assay
ELFA

EIA

ICA

Negative
Positive

53

26

Negative

6

16

Positive

50

12

Negative

9

30

Positive

44

19

Negative

15

23

Positive

50

11

Negative

9

31

Sensitivity (%)

Specificity (%)

Kappa

89.8

38.1

0.300

84.7

71.4

0.568

74.6

54.8

0.297

84.7

73.8

0.590
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Immunoblot assays are considered to have high
specificity for EBV serology; previous reports indicate
that the results generally correlate well with IFA (7,10–
12). Buisson et al. reported that immunoblot assays have
diagnostic capabilities for EBV infection (7). Altuglu et al.
reported an agreement between immunoblot assays and
IFA for EBNA-1 IgG and anti-VCA IgM, but less agreement
for anti-VCA IgG (10). Koidl et al. studied 60 IFA IgGand IgM-positive samples with VIDAS, and reported 45
identical results (11). The additional western blot testing
of the remaining 15 discrepant samples was reported to
reveal 5 secondary reactivations, 6 past infections, 2 true
primary infections, and 2 seronegative samples in their
study (11). Sener et al. obtained satisfactory results using
IFA, EIA, and western blotting for the serological diagnosis
of EBV (12). The use of various recombinant antigens in
line immune assays makes this method advantageous for
detecting EBV status. However, in our study, reactivations
were obtained only with the IFA test, and none of the
other tests could identify these patients. This may be due
to the relatively small number of samples. In this study,
we compared the results of an immunoblot assay with
those of the standard IFA method and obtained good
agreement for the detection of anti-VCA IgG and antiVCA IgM. However, there was less agreement between the
immunoblot assay and IFA for the detection of anti-EBNA
IgG.
ELFA is a widely used method for the diagnosis of
EBV infection that can automatically detect anti-VCA
IgM, anti-VCA/EA IgG, and anti-EBNA IgG. Numerous
studies have assessed the performance of ELFA as a
diagnostic method for infection. Comparisons between
ELFA and IFA led Koidl et al. to report that ELFA may be
an alternative to IFA testing, especially in high-throughput
laboratories (11). To establish EBV profiles without using
standard IFA measurements, Lupo et al. analyzed the
results of ELFA and chemiluminescence assays and found
that they performed similarly (13). We found a good
correlation between ELFA and IFA for the detection of
VCA IgG, VCA IgM, and EBNA IgG in this study. Of the
60 true past-infection cases, 54 were confirmed as past
infections by ELFA, while 6 of 11 primary infections were
confirmed as such by ELFA. These results may be due to
the interpretation of IFA IgG avidity tests, which provide
accurate information regarding disease state.
Enzyme immunoassays are relatively simple and rapid
methods that are conventionally used for the diagnosis of
EBV. Many studies have investigated the accuracy of EIA
for the diagnosis of EBV infection. Rea et al. evaluated
the acute and convalescent serological responses to EBV
using the ELISA and IFA methods, and they reported
ELISA to be a viable alternative to IFA (14). Feng et al.
compared the results of anti-VCA IgM measurements
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using chemiluminescent immunoassay (CLIA) with
those by ELISA in patients with infectious mononucleosis
and primary EBV infection detected by IFA (15). They
reported CLIA to be a more sensitive and specific method
than ELISA for the diagnosis of infectious mononucleosis.
Based on comparisons with IFA, Ory et al. reported that
immunofiltration, CLIA, and ELISA may be useful for the
diagnosis of EBV infections (16).
Devanthery et al. compared a bead-based assay with
EIA and IFA and observed a good qualitative correlation
among the 3 methods for detecting anti-VCA IgG and
IgM (17). IFA displayed a considerably reduced sensitivity
compared to the 2 other methods for the detection of antiEBNA antibodies. Gartner et al. evaluated 4 commercially
available EIAs using IFA as the reference method (18).
They reported that 2 of the 4 EIAs agreed well with the
reference IFA results for the distinction of a primary
infection from seronegativity and a past infection, possibly
constituting reasonable alternatives to the standard IFA
method. It was also speculated that both the quality of the
individual parameters and their interpretation are critical
factors in assay performance. Our results indicate that EIA
measurements correlated well with IFA for the detection
of VCA IgG; however, both VCA IgM and EBNA IgG
correlated with the IFA results only weakly.
The literature indicates that ICA has yet to be
investigated as a diagnostic tool for EBV infection. To
evaluate its effectiveness, we compared ICA with the
standard procedure (IFA), and found it to be mostly in
agreement. The ICA procedure is simple and does not
require specialist equipment. The ease of use and the
significantly higher sensitivity and specificity of ICA make
it a good choice for the diagnostic testing of EBV infection.
Here we compared 4 methods that are used to detect
antibodies against EBV (immunoblot assay, ELFA, EIA, and
ICA) with the standard IFA method using a limited number
of serum samples. Our results demonstrate that ELFA and
ICA were in agreement with the standard IFA method for
VCA IgM, VCA IgG, and EBNA IgG detection. There was
less agreement between the results of IFA and those of
both the immunoblot assay and EIA for EBNA IgG. The
EIA results were also less in agreement with IFA for VCA
IgM. After considering test cost-effectiveness, turnaround
time, requirements for specialist equipment, and IFA
concordance, we conclude that both ELFA and ICA may be
suitable methods for the diagnosis and staging of EBV.
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